Garraway et al. (2006) have observed that MITF gene amplification in metastatic melanoma coincides with BRAFV600E mutation and p16 inactivation, promoting tumor growth and survival, while MITF reduction exposes melanoma to conventional chemotherapeutic sensitization [29]. This evidence concerns the gene MITF and neoplasm.